Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2022

27-08-2022 | Melanoma | Author Correction

Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine

Authors: Haiqin Ping, Wenjun Yu, Xiaoming Gong, Xin Tong, Cheyu Lin, Zhaojun Chen, Caiyun Cai, Kai Guo, Hengning Ke

Published in: Investigational New Drugs | Issue 6/2022

Login to get access

Excerpt

Author information was missing and will be added. …
Metadata
Title
Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
Authors
Haiqin Ping
Wenjun Yu
Xiaoming Gong
Xin Tong
Cheyu Lin
Zhaojun Chen
Caiyun Cai
Kai Guo
Hengning Ke
Publication date
27-08-2022
Publisher
Springer US
Keywords
Melanoma
Melanoma
Published in
Investigational New Drugs / Issue 6/2022
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-022-01296-6

Other articles of this Issue 6/2022

Investigational New Drugs 6/2022 Go to the issue

Research

Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations

Case Report

A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report

Research

Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer

Research

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Research

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

Research

Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits